460 related articles for article (PubMed ID: 31208705)
61. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
[TBL] [Abstract][Full Text] [Related]
62. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
[TBL] [Abstract][Full Text] [Related]
63. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Cardiovasc Drugs Ther; 2016 Jun; 30(3):297-304. PubMed ID: 26936841
[TBL] [Abstract][Full Text] [Related]
64. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
[TBL] [Abstract][Full Text] [Related]
65. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
[TBL] [Abstract][Full Text] [Related]
66. Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment.
Holven KB; Narverud I; Lindvig HW; Halvorsen B; Langslet G; Nenseter MS; Ulven SM; Ose L; Aukrust P; Retterstøl K
Atherosclerosis; 2014 Apr; 233(2):561-567. PubMed ID: 24530965
[TBL] [Abstract][Full Text] [Related]
67. Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.
Mattina A; Rosenbaum D; Bittar R; Bonnefont-Rousselot D; Noto D; Averna M; Bruckert E; Giral P
Nutr Metab Cardiovasc Dis; 2018 May; 28(5):517-523. PubMed ID: 29525223
[TBL] [Abstract][Full Text] [Related]
68. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.
Huijgen R; Abbink EJ; Bruckert E; Stalenhoef AF; Imholz BP; Durrington PN; Trip MD; Eriksson M; Visseren FL; Schaefer JR; Kastelein JJ;
Clin Ther; 2010 Apr; 32(4):615-25. PubMed ID: 20435231
[TBL] [Abstract][Full Text] [Related]
69. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
Brandts J; Tittel SR; Bramlage P; Danne T; Brix JM; Zimny S; Heyer CHJ; Holl RW; Müller-Wieland D
Diabetes Obes Metab; 2023 Dec; 25(12):3700-3708. PubMed ID: 37694759
[TBL] [Abstract][Full Text] [Related]
70. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.
Bissonnette S; Habib R; Sampalis F; Boukas S; Sampalis JS;
Can J Cardiol; 2006 Oct; 22(12):1035-44. PubMed ID: 17036098
[TBL] [Abstract][Full Text] [Related]
71. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
72. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
73. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
Ramaswami U; Futema M; Bogsrud MP; Holven KB; Roeters van Lennep J; Wiegman A; Descamps OS; Vrablik M; Freiberger T; Dieplinger H; Greber-Platzer S; Hanauer-Mader G; Bourbon M; Drogari E; Humphries SE
Atherosclerosis; 2020 Jan; 292():178-187. PubMed ID: 31809987
[TBL] [Abstract][Full Text] [Related]
74. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
75. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
Rallidis LS; Kiouri E; Katsimardos A; Kotakos C
Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053
[TBL] [Abstract][Full Text] [Related]
76. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
Ito MK; Watts GF
Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
[TBL] [Abstract][Full Text] [Related]
77. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
78. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
[TBL] [Abstract][Full Text] [Related]
79. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
[TBL] [Abstract][Full Text] [Related]
80. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.
Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Yazdi D; Elliott-Davey M; Mues KE; Bhatt DL; Kosiborod MN;
Am Heart J; 2020 Jan; 219():70-77. PubMed ID: 31726422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
